Abstracts tagged "longitudinal studies"

Abstract Number: 2196 • 2016 ACR/ARHP Annual Meeting
Trajectories and Predictors of Fear-Avoidance in Persons with Rheumatoid Arthritis. a Longitudinal Observational Study
Christina H. Opava¹, Annika Björk², Alyssa B. Dufour^1,3, Birgitta Nordgren¹ and Ingrid Demmelmaier⁴, ¹Department of Neurobiology, Care Sciences and Society, Division of Physiotherapy, Karolinska Institutet, Huddinge, Sweden, ²Nacka Rehabilitation Center, Stockholm County Council, Nacka, Sweden, ³Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School & Beth Israel Deaconess Medical Center, Boston, MA, ⁴Neurobiology, Care Sciences & Society, Karolinska Institutet, Huddinge, Sweden
Trajectories and Predictors of Fear-Avoidance in Persons With Rheumatoid Arthritis. A Longitudinal Observational Study Background/Purpose: Rheumatoid arthritis (RA) is a chronic, inflammatory disease with…
Abstract Number: 2370 • 2016 ACR/ARHP Annual Meeting
Factors Affecting Interval Changes in Perceived Fatigue over Five Years in Patients with Rheumatoid Arthritis Compared with Osteoarthritis
Simon Stebbings^1,2, Gareth Treharne³, J. Haxby Abbott⁴ and Andrew Gray⁵, ¹Dunedin Hospital, Department of Rheumatology, Dunedin, New Zealand, ²Department of Medicine, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand, ³Psychology, University of Otago, Dunedin, New Zealand, ⁴Centre for Musculoskeletal Outcomes Research, Department of Surgical Sciences, University of Otago, Dunedin, New Zealand, ⁵Department of Preventive and Social Medicine, University of Otago, Dunedin, New Zealand
Background/Purpose: In a previous cross-sectional study we noted higher fatigue levels in patients with advanced lower limb OA compared with RA, and identified differences in…
Abstract Number: 3132 • 2016 ACR/ARHP Annual Meeting
Protective Effects of Replacing Sedentary Time with Light and Moderate to Vigorous Physical Activity on Functional Limitation in Knee OA
Daniel White, Department of Physical Therapy, University of Delaware, Newark, DE
Background/Purpose: Physical activity protects the development of functional limitation in knee osteoarthritis (OA). But little is known about the protective effects of physical activity intensity,…
Abstract Number: 3212 • 2016 ACR/ARHP Annual Meeting
Treat-to-Target in RA: Does Early Simplified Disease Activity Index (SDAI) Remission Lead to Better 5-Year Functional Outcomes Than SDAI Low Disease Activity?
Vibeke Norvang, Elisabeth Lie, Inge C Olsen, Eirik K Kristianslund, Tore K Kvien and Till Uhlig, Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: The management of rheumatoid arthritis (RA) has evolved considerably during the last couple of decades, with current recommended practice being a treat-to-target approach, involving…
Abstract Number: 116 • 2016 ACR/ARHP Annual Meeting
Racial Differences in Self-Reported Pain and Disability: A Longitudinal Study of Knee Osteoarthritis
Ernest Vina¹, Di Ran², Erin Ashbeck² and C. Kent Kwoh³, ¹Rheumatology, University of Arizona, Tucson, AZ, ²University of Arizona, Tucson, AZ, ³Rheumatology, University of Arizona, College of Medicine, Tucson, AZ
Background/Purpose: Pain and disability from knee osteoarthritis (KOA) has been reported to be greater among African-Americans (AAs) than Whites (WHs), though progression in KOA-related…
Abstract Number: 906 • 2016 ACR/ARHP Annual Meeting
Treatment with Methotrexate and Risk of Relapses in Patients with Giant Cell Arteritis in Clinical Practice
Luis Rodriguez Rodriguez¹, Leticia Leon², Inmaculada Morado¹, Zulema Rosales Rosado², Cristina Vadillo Font¹, Dalifer Freites Núñez¹, Pilar Macarrón¹, Benjamín Fernández-Gutiérrez³, Juan A Jover Jover² and Lydia Abásolo Alcázar², ¹Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ²Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, ³Department of Rheumatology, Hospital Clinico San Carlos, Madrid, Spain
Background/Purpose: Several Clinical trials indicate that Methotrexate (MTX) could be considered as a feasible option in addition to corticosteroids for patients with GCA, but there…
Abstract Number: 968 • 2016 ACR/ARHP Annual Meeting
Urinary Soluble CD163, an M2 Macrophage Marker, Reflects the Renal Disease Activity in Lupus Nephritis: A Cross Sectional and Longitudinal Assessment
Ranjan Gupta¹, Akhilesh Yadav² and Amita Aggarwal¹, ¹Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: Alternatively activated (M2) macrophages are the major macrophage subtype infiltrating the glomeruli in lupus nephritis (LN). CD163 is a marker of M2 macrophages. In…
Abstract Number: 1019 • 2016 ACR/ARHP Annual Meeting
The Impact of Hip and Knee Osteoarthritis on the Subsequent Risk of Incident Diabetes: A Population-Based Cohort Study
Tetyana Kendzerska^1,2,3, Lauren King¹, Ruth Croxford², Ian Stanaitis³, Angela Wall³ and Gillian Hawker^1,2,3, ¹University of Toronto, Toronto, ON, Canada, ²Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, ³Women's College Research Institute/Women's College Hospital, Toronto, ON, Canada
Background/Purpose: Osteoarthritis (OA) and diabetes commonly co-occur. Potential explanations include common risk factors (aging, obesity) and the effects of OA-related functional limitations on diabetes risk…
Abstract Number: 1221 • 2016 ACR/ARHP Annual Meeting
Environmental Scan of Rheumatoid Arthritis Patient Registries Around the World: An Omeract Initiative
Natalia V. Zamora¹, Maria A. Lopez-Olivo², Robin Christensen³, Niti Goel^4,5, Lars Erik Kristensen⁶, Vibeke Strand⁷, Jeffrey R. Curtis⁸, Beverly Shea⁹ and Maria Suarez-Almazor¹⁰, ¹Section of Rheumatology and Clinical Immunology, The University of Texas, MD Anderson Cancer Center, Houston, TX, ²General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ³Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark, ⁴Rheumatology Center of Excellence, Quintiles, Durham, NC, ⁵Duke University School of Medicine, Durham, NC, ⁶The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark, ⁷Biopharmaceutical Consultant, Portola Valley, CA, ⁸Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁹Department of Clinical Epidemiology & Biostatistics, McMaster University, Health Science Centre Hamilton, Ontario, ON, Canada, ¹⁰Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Houston, TX
Background/Purpose: Patient registries both disease-and drug-based complement information obtained from clinical trials. Long-term outcomes studies can provide information useful for patients. The Agency for Healthcare…
Abstract Number: 1984 • 2016 ACR/ARHP Annual Meeting
Which Factors Associate with Localized Knee Pain and Generalized Pain: A 10-Year Longitudinal Study?
Feng Pan¹, Dawn Aitken², Jing Tian³, Flavia M Cicuttini⁴, Changhai Ding² and Graeme Jones², ¹Musculoskeletal Unit, Menzies Institute for Medical Research, University of Tasmania, Hobart,7000, Australia, ²Musculoskeletal Unit, Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia, ³Public health unit, Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia, ⁴Monash University, Department of Epidemiology and Preventive Medicine, Melbourne, Australia
Background/Purpose: The correlates of localized knee pain (KP) and multi-site pain (MSP) have been clearly demonstrated; however, whether these factors also contribute to intermittent or…
Abstract Number: 2019 • 2016 ACR/ARHP Annual Meeting
Faces in Motion: Clinical Subtyping in Scleroderma Using Changes in Forced Vital Capacity
Colin Ligon¹, Peter Schulam², Suchi Saria³, Fredrick M. Wigley⁴, Robert Wise⁵ and Laura K. Hummers⁶, ¹Rheumatology, University of Pennsylvania School of Medicine, Philadelphia, PA, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ⁴Rheum Div/Mason F Lord, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Department of Pulmonology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Prognostication in scleroderma has historically depended on using static measures such as antibody status and extent of skin involvement to stratify risk of mortality…
Abstract Number: 2168 • 2016 ACR/ARHP Annual Meeting
Metabolic Syndrome, All Cause Mortality and Atherosclerotic Cardiovascular Disease in Rheumatic Diseases
Marco Antivalle^1,2, Valentina Varisco², Alessandra Mutti², Alberto Batticciotto², Maria Chiara Ditto², Fabiola Atzeni³ and Piercarlo Sarzi-Puttini², ¹Rheumatology, Rheumatology Unit, ASST Fatebenefratelli - Sacco, L. Sacco University Hospital, Milano, Italy, ²Rheumatology Unit, ASST Fatebenefratelli - Sacco, L. Sacco University Hospital, Milan, Italy, ³Rheumatology Unit, ASST Fatebenefratelli - Sacco, L. Sacco University Hospital, Milano, Italy
Background/Purpose: all-cause and cardiovascular mortality and cardiovascular morbidity are reportedly increased in rheumatic diseases, both inflammatory and non-inflammatory. Few studies, however have addressed the impact…
Abstract Number: 716 • 2015 ACR/ARHP Annual Meeting
Urinary Proteomics Identifies Three Novel Biomarkers for Lupus Nephritis Activity: Retinol Binding Protein, Alpha-1-Antichymotrysin and Haptoglobin
Amita Aggarwal¹, Sudhir sinha², Ranjan Gupta³, Liza Rajasekhar⁴, Akhilesh Yadav³, Ramnath Misra¹ and Virsingh Negi⁵, ¹Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Department of Biochemistry, CSIR-central drug research institute, Lucknow, India, ³Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ⁴Department of Rheumatology, Nizam Institute of Medical Sciences, Hyderabad, India, ⁵Department of Clinical Immunology, JIPMER, Puducherry, India
Background/Purpose: Urinary biomarkers have a potential for identification, follow-up and assessment of response to treatment in patients with lupus nephritis. Urinary proteomics can help in…
Abstract Number: 849 • 2015 ACR/ARHP Annual Meeting
A Computational Tool for Individualized Prognosis of Percent of Predicted Forced Vital Capacity Trajectories in Systemic Sclerosis
Peter Schulam¹, Colin Ligon², Robert Wise³, Laura K. Hummers⁴, Fredrick M. Wigley⁵ and Suchi Saria^1,6, ¹Department of Computer Science, Johns Hopkins University, Baltimore, MD, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Department of Pulmonology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Rheum Div/Mason F Lord, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Departments of Biostatistics, and Health Policy and Management, Bloomberg School of Public Health, Baltimore, MD
Background/Purpose: Interstitial lung disease (ILD) is a common cause of mortality in systemic sclerosis (Ssc). Decreased forced vital capacity (FVC) in Ssc-ILD is associated with…
Abstract Number: 1645 • 2015 ACR/ARHP Annual Meeting
Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Clinical and Radiographic Efficacy in Open-Label, Long-Term Extension Studies over 7 Years
Jürgen Wollenhaupt¹, Joel Silverfield², Eun Bong Lee³, Ketti Terry⁴, Kenneth Kwok⁵, Irina Lazariciu⁶, Chudy Nduaka⁷, Carol A. Connell⁴, Ryan DeMasi⁵ and Lisy Wang⁴, ¹Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ²Healthpoint Medical Group, Tampa, FL, ³Seoul National University, Seoul, South Korea, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, New York, NY, ⁶Quintiles, Saint-Laurent, QC, Canada, ⁷Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We report tofacitinib safety, tolerability, and clinical response over 84 months…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].